Figure 4.

The specific antioxidant NAC reduced low-dose Cr(VI)-induced mitochondria dysfunction. (a) The NAC was used before Cr(VI) exposure in L02 hepatocytes, (a) then ΔΨm was assayed by JC-1 using spectrofluorometry. (b) Mitochondria mass was assayed by NAO kit, and (c) mtDNA copy number was analyzed by RT-PCR. (d) Mitochondrial morphology was determined by Mito-Tracker Red CMXRos (red) (200x). All experiments were repeated at least 3 times and expressed as mean ± SD. ^∗p < 0.05, compared with control; ^#p < 0.05, compared with Cr(VI)-exposed group.